Zydus Lifesciences

Ahead of the buyback opening, Zydus Life stock was trading 2.5% lower at ₹ 1,063 apiece on Tuesday, 2 June. Here are the buyback details, along with experts' opinions on whether retail investors should participate.

Zydus Lifesciences announced an increase in its share buyback pricebut a cut in the number of shares offered. Here's the new buyback price, along with other revised details of the offer.

Zydus Lifesciences shares rose over 6% after strong Q4FY26 earnings, reporting a 14.6% increase in net profit to ₹ 1,592.9 crore. Revenue grew to ₹ 7,587 crore, driven by the consumer wellness segment. The board approved a ₹ 1,100 crore share buyback and a Re 1 dividend.

For FY26, its revenue from operations stood at ₹ 27,148.4 crore, up 17% on-year, and adjusted net profit grew 15% to ₹ 5,456.4 crore.

The Indian stock market rebounded on May 14, with the Sensex up 790 points. Analysts recommend buying stocks like Nippon Life India Asset Management and Zydus Lifesciences, citing strong market conditions despite geopolitical tensions and high oil prices.

Zydus Lifesciences board will meet on May 19 to address potential share buyback details. Market participants are now expected to closely track the size, pricing, and structure of the proposed buyback if approved by the board.

Stock market today: The Indian stock market is likely to continue its gaining streak as trends in the Gift Nifty index signalled a higher opening on Thursday. Amid this backdrop, these stocks will remain in focus on 14 May.

Cipla, Dr Reddy’s Laboratories, and Zydus Lifesciences are among the most affected by the US sales decline.